Advertisement
Advertisement

AKTS

AKTS logo

Aktis Oncology, Inc. Common stock

23.89
USD
Sponsored
-0.12
-0.50%
Jul 24, 15:59 UTC -4
Closed
exchange

After-Market

23.88

-0.01
-0.04%

AKTS Earnings Reports

Positive Surprise Ratio

AKTS beat 1 of 2 last estimates.

50%

Next Report

Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/
--
Implied change from Q1 26 (Revenue/ EPS)
--
/
--
Implied change from Q-- -- (Revenue/ EPS)
--
/
--

Aktis Oncology, Inc. Common stock earnings per share and revenue

On May 11, 2026, AKTS reported earnings of -0.38 USD per share (EPS) for Q1 26, missing the estimate of -0.34 USD, resulting in a -11.54% surprise. Revenue reached 3.23 million, compared to an expected 1.78 million, with a 80.78% difference. The market reacted with a +7.99% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Summit Therapeutics Inc. Common Stock
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.28
Actual
-$0.28
Surprise
+1.72%
FAQ
For Q1 2026, Aktis Oncology, Inc. Common stock reported EPS of -$0.38, missing estimates by -11.54%, and revenue of $3.23M, 80.78% above expectations.
The stock price moved up 7.99%, changed from $18.27 before the earnings release to $19.73 the day after.
The next earning report is scheduled for --.
Based on -- analysts, Aktis Oncology, Inc. Common stock is expected to report EPS of -- and revenue of -- for Q-- --.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement